Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women

Inclusion Criteria: * Males and females aged 18-85 years who have given written informed consent. * Subjects with a body mass index within 15-35 kg/m2 (Quetelet's index). Exclusion Criteria: * Subjects with history or evidence of keloid scarring. * Subjects with tattoos or previous scars within 3cm of the area to be incised. * Subjects who had surgery in the area to be incised within one year of the first dosing day. * Subjects with history of a bleeding disorder or who were receiving anti-coagulant or anti-platelet therapy. * Subjects with evidence of any past or present clinically significant disease that may affect the endpoints of the trial. * Subjects with a clinically significant skin disorder that was chronic or currently active. * Subjects with any clinically significant medical condition or history that would impair wound healing. * Subjects with history of hypersensitivity to any of the drugs or dressings used in this trial. * Subjects taking, or who have taken, any investigational product or who had participated in a clinical trial in the three months prior to first trial dose administration. * Subjects taking regular, continuous, oral corticosteroid therapy. * Subjects undergoing investigations or changes in management for an existing medical condition. * Subjects with a history of drug abuse, or with a positive drugs of abuse test for cocaine, amphetamines, methamphetamines, opiates or benzodiazepines during the screening period. * Subjects who, in the opinion of the investigator, were unlikely to complete the trial for whatever reason. * Subjects who had any clinically significant neurological impairment or disease. * Subjects with any active infection. * Subjects who are pregnant or lactating.